Frauenfeld, 12 April 2023

Press release

Zur Rose Group AG publishes invitation to the Annual General Meeting on 4 May 2023

The Zur Rose Group has today published the invitation to the Annual General Meeting on 4 May 2023.

In addition to the standard agenda items and the formal implementation of the revised Swiss Corporate Law, the Board of Directors proposes the creation of a capital band to replace the authorised capital with an upper limit of 120 per cent of the registered share capital. An additional proposal is the creation of new conditional capital for financing and other purposes of 20 per cent of the share capital. With this, the Board of Directors would like to maintain the financial flexibility of the Zur Rose Group for opportunities as they arise. The two proposals are linked by limiting the total increase authority of the Board of Directors to 20 per cent and its authority to exclude subscription or preemptive rights to 10 per cent (so-called cumulative dilution cap).

For the envisaged structure of the employee participation plans, the Board of Directors also proposes to increase the conditional capital for employee participation again to just under 3 per cent of the share capital.

With the sale of the Swiss business to Medbase, the “Zur Rose” brand will also be transferred. Though, Zur Rose Group AG has the right to continue using the brand during a transitional period. In this context, the Board of Directors proposes that Zur Rose Group AG be renamed to DocMorris AG – the core brand for the B2C business in Germany.

The invitation to the Annual General Meeting with the complete agenda is available at the following link: https://ir.zurrosegroup.com/en/investor-relations/corporate-governance/general-meeting

Investors and analyst contact
Dr. Daniel Grigat, Group Head of Investor Relations & Sustainability
Email: ir@zurrose.com, phone: +41 58 810 11 49

Media contact
Lisa Lüthi, Group Director Communications
Email: media@zurrose.com, phone: +41 52 724 08 14

Agenda

Zur Rose Group
The Swiss-based Zur Rose Group is Europe’s largest online pharmacy and one of the leading wholesale suppliers to medical doctors in Switzerland. It also operates the leading marketplace for health and personal care products in southern Europe. The company is internationally present with strong brands – including DocMorris, Germany's best-known health platform. With its business model, the Zur Rose Group offers patients, customers and partners a broad range of products and services in the fields of e-commerce pharmacy, marketplace and professional health. In doing so, Zur Rose is pursuing its vision of creating a world for everyone to manage their health in one click. In 2022, about 2,700 employees in Switzerland, Germany, the Netherlands, Spain and France generated an external revenue of CHF 1,837 million serving more than 10 million active customers. The shares of Zur Rose Group AG are listed on the SIX Swiss Exchange (securities number 4261528, ISIN CH0042615283, ticker ROSE). For further information, please visit zurrosegroup.com.